Skip to main content
padlock icon - secure page this page is secure

Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin

Buy Article:

$43.00 + tax (Refund Policy)

Abstract Background: 

The IRESSA Survival Evaluation in Lung cancer (ISEL) trial showed some improvement in survival which failed to reach statistical significance in the overall population and in patients with adenocarcinoma. However, gefitinib (IRESSA) treatment was associated with a significant improvement in the survival in subgroups of patients of Asian origin and never smokers. Here we review the clinical experience of gefitinib in patients of Asian origin with advanced non-small cell lung cancer (NSCLC) and discuss the evidence for the underlying biological basis for the apparent heterogeneity in clinical outcome between patients of Asian and non-Asian origin. Methods: 

Reports of clinical experience with gefitinib 250 mg/day in Asia were identified by searching Embase and Medline databases for publications between 1 January 2003 and 27 July 2006. Results: 

A large number of reports in patients of Asian origin show high objective response and disease-control rates with gefitinib treatment, with median survival >6 months and time to progression >3 months. The reports also indicate that gefitinib is generally well tolerated by patients of Asian origin and epidermal growth factor receptor (EGFR) mutations, which appear to be associated with gefitinib sensitivity, occur at a much higher rate in these patients compared with patients of non-Asian origin. These reports also indicate that a high EGFRgene copy number may be associated with their response to gefitinib. Conclusion: 

Gefitinib appears to be a valid, efficacious, and generally well-tolerated treatment option for patients of Asian origin with advanced NSCLC. It is possible that differences in EGFR mutation rates may underlie variations in response rates to gefitinib between Asian and non-Asian patient populations. Further exploratory analyses conducted in prospective clinical trials are required to fully determine the role of EGFR mutations, a high EGFR gene copy number and other biomarkers in determining the response to gefitinib treatment.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: EGFR; ISEL; NSCLC; gefitinib; mutation

Document Type: Research Article

Publication date: 01 June 2007

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more